Adenoviral infection or deferoxamine? Two approaches to overexpress VEGF in β-cell lines

Abstract

Rapid and adequate revascularization of transplanted islets is important for their survival and function during transplantation. Vascular endothelial growth factor (VEGF) could play a critical role with respect to islet revascularization. The aim of this study was to compare two strategies that are used to overexpress VEGF in β-cells: (1) gene therapy through adenoviral infection and (2) a pharmacological approach using deferoxamine (DFO). β-Cell lines from rat insulinoma (RINm5F) were either infected using an adenovirus encoding the gene of human VEGF 165 or incubated with DFO. One day after treatment, the viability of RINm5F cells was preserved with 10 μmol/L of DFO (103.95 ± 5.66% toward control; n = 4). In addition, adenoviral infection maintained the viability of cells for all the concentrations used. In both treatments, overexpression of VEGF was in a comparable level. Finally, the ratio of Bax/Bcl-2 indicated that the apoptosis increased in infected β-cells whereas treatment with DFO seems to be antiapoptotic. Our results suggest that the use of DFO could be a realistic approach to improve the vascularization of islets during transplantation.

Keywords::

• β-cells
• angiogenesis
• VEGF
• adenovirus
• deferoxamine
• hypoxia
• HIF-1α
• apoptosis
• gene therapy
• insulin

Acknowledgements

Declaration of interest: The authors report no conflicts of interest.